Branched Linkers for Homogeneous Antibody-Drug Conjugates: How Long Is Long Enough?

Area of Science:

• Bioconjugation Chemistry
• Antibody-Drug Conjugates (ADCs)
• Protein Engineering

Background:

• Homogeneous antibody-drug conjugates (ADCs) offer superior pharmacological profiles over heterogeneous ADCs.
• Enzymatic conjugation, such as using microbial transglutaminase (MTGase), enables site-specific payload attachment for homogeneity.
• Branched linkers are necessary for achieving higher drug-to-antibody ratios (DARs) in homogeneous ADCs, but their structural impact is poorly understood.

Purpose of the Study:

• To investigate the relationship between branched linker structure and the properties of homogeneous ADCs.
• To synthesize and evaluate homogeneous trastuzumab-based ADCs with varying branched linker lengths and drug-to-antibody ratios (DARs).

Main Methods:

• Synthesis of two branched amino triazide linkers with differing lengths (incorporating a PEG4 fragment).
• Preparation of homogeneous trastuzumab-ADCs (DAR 6, 'short' and 'long' linkers) via enzymatic conjugation (MTGase) and bioorthogonal coupling with monomethyl auristatin E (MMAE).
• Characterization of control ADCs: heterogeneous DAR 6 and homogeneous DAR 2 trastuzumab-MMAE conjugates.

Main Results:

• All four trastuzumab-MMAE conjugates exhibited similar binding affinity to HER2.
• Cytotoxicity varied significantly: the 'long' homogeneous DAR 6 ADC matched the potency of the heterogeneous DAR 6 control.
• The 'short' homogeneous DAR 6 ADC showed significantly reduced potency, being less effective than the DAR 2 conjugate.

Conclusions:

• Branched linker length is a critical determinant of ADC cytotoxic activity.
• Steric hindrance introduced by shorter branched linkers may impede lysosomal enzyme cleavage, reducing drug release and potency.
• Enzymatic conjugation offers a viable route for creating homogeneous ADCs with tunable properties based on linker design.